The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimer'sDisease from Non-Alzheimer's Dementia

Spies, Petra E.; Slats, Diane; Sjögren, Julia; Kremer, Berry; Verhey, Frans R.J.; Rikkert, Marcel G M Olde; Verbeek, Marcel M.

doi:10.2174/1567210200438122050

Cited by 24 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Ab 1-42 :Ab 1-40 ratio has been shown to have added value with respect to Ab 1-42 alone, giving an accuracy of .80% for distinguishing AD at both the prodromal and the dementia stage compared with other neurodegenerative dementias [35][36][37][38].…”

Section: Ad Csf Biomarkers Used and Cutoff Valuesmentioning

confidence: 99%

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Molinuevo

Blennow

Dubois³

et al. 2014

Alzheimer's & Dementia

172

136

View full text Add to dashboard Cite

show abstract

Section: Ad Csf Biomarkers Used and Cutoff Valuesmentioning

confidence: 99%

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Molinuevo

Blennow

Dubois³

et al. 2014

Alzheimer's & Dementia

172

136

View full text Add to dashboard Cite

show abstract

“…The increase in the ratio of Aβ42/Aβ40 is typical of AD patients [62]. Majority of Aβ peptides is secreted from the neurons as Aβ40.…”

Section: Aβ β Functionmentioning

confidence: 99%

Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review

Šerý¹,

Povová²,

Mı́šek³

et al. 2013

147

View full text Add to dashboard Cite

show abstract

“…Low levels of Aβ42 in cerebrospinal fluid (CSF) are related to AD and are believed to reflect accumulation of senile plaques in brain parenchyma [16,17]. Aβ40, on the other hand, is the most abundant Aβ peptide [18]. Its biochemical function is unclear, but high levels of Aβ40 are suggested to reflect Aβ overproduction and amyloid precursor protein (APP) dysfunction [19].…”

Section: Introductionmentioning

confidence: 99%

Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: A 25-Year Follow-Up Study

Johansson

Kern

Zetterberg

et al. 2018

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background/Aims: Psychological stress has previously been associated with higher risk of developing late-life dementia, especially Alzheimer’s disease (AD). This study tested whether longstanding midlife stress is related to cerebrospinal fluid (CSF) biomarkers of late-life AD, such as tau protein and amyloid beta (Aβ). Methods: The study included 79 nondemented females from the Prospective Population Study of Women in Gothenburg, Sweden, who responded to a standardized stress question at baseline (mean age 49 years) and underwent a lumbar puncture at follow-up 25 years later. Multiple linear regression models analyzed the relationships between midlife psychological stress and late-life CSF measures of total tau (t-tau), phosphorylated tau (p-tau), Aβ40, and Aβ42. Results: Longstanding stress in midlife was associated with higher levels of CSF t-tau (β = 0.64, p = 0.01) and Aβ40 (β = 0.60, p = 0.02) in late life. No associations were found between midlife stress and levels of p-tau or Aβ42. Conclusion: The findings suggest that longstanding stress stimulates unspecific neurodegenerative processes, but not the core processes of AD, at least not in the early phase of the disease. The association with higher concentration of CSF t-tau may reflect neural degeneration and the association with higher Aβ40 may be an early sign of Aβ overproduction or cerebrovascular processes in the brain.

show abstract

The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimer'sDisease from Non-Alzheimer's Dementia

Cited by 24 publications

References 0 publications

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review

Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: A 25-Year Follow-Up Study

Contact Info

Product

Resources

About